Skip to main content
main-content

Haematology

Latest articles

11-12-2018 | Oncology | Highlight | Article

Editor's pick

Direct oral anticoagulants AVERT VTE events in patients with cancer

The results of the randomized CASSINI and AVERT trials support the prophylactic use of the direct oral anticoagulants rivaroxaban and apixaban in cancer patients undergoing chemotherapy who are at risk for venous thromboembolism events.

Source:

ASH 2018; San Diego, California, USA; 1–4 December
N Engl J Med 2018; doi:10.1056/NEJMoa1814468

10-12-2018 | Lymphoma | News | Article

Long-term data further support axicabtagene ciloleucel use for refractory large B-cell lymphoma

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30864-7
ASH 2018; San Diego, California, USA; 1–4 December

06-12-2018 | Leukaemia | News | Article

Ibrutinib delays progression versus chemoimmunotherapy in older CLL patients

Treatment with ibrutinib either alone or in combination with rituximab significantly delays disease progression or death compared with bendamustine plus rituximab in older patients with untreated chronic lymphocytic leukaemia, phase III trial data show.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1812836
ASH 2018; San Diego, California, USA; 1–4 December

05-12-2018 | Lymphoma | News | Article

Editor's pick

Durable response to tisagenlecleucel shown in DLBCL

Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1804980
ASH 2018; San Diego, California, USA; 1–4 December

04-12-2018 | Oncology | Video

Prophylactic treatment with rivaroxaban reduces cancer patients' VTE risk

Study author Alok Khorana discusses the results of the CASSINI trial, demonstrating a reduction in venous thromboembolism during treatment with rivaroxaban among patients with cancer (2:54).

19-10-2018 | Oncology | News | Article

Post-induction PET predicts outcome in follicular lymphoma

Patients with follicular lymphoma who achieve a positron emission tomography-determined complete response to induction immunochemotherapy have a significantly better prognosis than those with a non-complete response, research shows.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30618-1

17-10-2018 | Oncology | News | Article

Editor's pick

Duvelisib offers treatment alternative for patients with CLL/SLL

The oral, dual inhibitor of phosphoinositide 3-kinase-δ and –γ duvelisib significantly delays disease progression or death compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, data from the DUO trial show.

Source:

Blood 2018; doi:10.1182/blood-2018-05-850461

05-10-2018 | Oncology | News | Article

approvalsWatch

NGS test approved for ALL, multiple myeloma residual disease

The US FDA announcement is reported here

28-09-2018 | Oncology | News | Article

In other news: Hematologic cancer focus

This month we round-up four hematologic cancer trials, two looking at treatment options for older and younger patients with Hodgkin lymphoma, and two evaluating treatments for smoldering and relapsed or refractory multiple myeloma. Read on to find out more.

20-09-2018 | Lymphoma | News | Article

Hormonal biomarker shows ovarian toxicity of Hodgkin lymphoma treatment

Phase III trial data have highlighted the value of antimüllerian hormone as a biomarker of ovarian toxicity associated with different chemotherapy regimens for advanced Hodgkin lymphoma.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30500-X

19-09-2018 | Oncology | News | Article

Persistent mutations post-transplant predict MDS disease progression

Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.

Source:

N Engl J Med 2018; 379: 1028–1041

18-09-2018 | Oncology | News | Article

Allogeneic HSCT-treated patients often receive medically intense end-of-life care

A US research team has found that end-of-life care among individuals who undergo allogeneic hematopoietic stem cell transplantation can often be medically intense.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.095

07-09-2018 | Lymphoma | News | Article

Circulating tumor DNA predicts DLBCL outcomes

Pretreatment levels of circulating tumor DNA, as well as changes during therapy, are independently prognostic of outcomes in patients with diffuse large B-cell lymphoma and can add to established risk factors, findings indicate.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.5246

06-09-2018 | Lymphoma | News | Article

Lenalidomide plus rituximab comparable to follicular lymphoma standard of care

Treatment-naïve follicular lymphoma patients have similar outcomes regardless of whether they receive lenalidomide or chemotherapy in combination with rituximab, suggest phase III trial findings published in The New England Journal of Medicine.

Source:

N Engl J Med 2018; 379: 934–947

21-08-2018 | Oncology | News | Article

Lenalidomide ‘the best maintenance option’ for newly diagnosed multiple myeloma

Lenalidomide offers the best overall and progression-free survival among novel agent-based maintenance regimens in patients with newly diagnosed multiple myeloma, according to a systematic review and network meta-analysis.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.2961

13-08-2018 | Oncology | News | Article

Ibrutinib monotherapy promising for untreated Waldenström macroglobulinemia

Phase II trial results suggest that the Bruton tyrosine kinase inhibitor ibrutinib has high activity and is well tolerated in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.6426
J Clin Oncol 2018; doi:10.1200/JCO.2018.79.3273

13-08-2018 | Oncology | News | Article

approvalsWatch

Mogamulizumab-kpkc approved for rare NHL subtypes

Read more on this US FDA decision here

30-07-2018 | Leukaemia | Main feed | News

approvalsWatch

Ivosidenib, filgrastim biosimilar receive approvals

Click here to read more on these US FDA decisions

06-04-2018 | Oncology | News | Article

In other news

In this month’s roundup, we cover topics including laboratory eligibility criteria as a potential barrier to clinical participation and the impact of cognitive dysfunction on survival in patients with hematologic cancers. Read on to find out more.

02-03-2018 | Oncology | News | Article

Next-generation PI3Kδ inhibitor umbralisib warrants further investigation

The phosphatidylinositol 3-kinase isoform p110δ inhibitor umbralisib has shown preliminary activity against relapsed or refractory hematologic malignancies, with fewer autoimmune-like toxicities than other drugs in its class, researchers report.

Source:

Lancet Oncol 2018; Advance online publication

image credits